PHATHOM PHARMACEUTICALS, INC. Research and Development in Process
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Research and Development in Process of $78.90 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2021-03-30
- PHATHOM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2019-12-31 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. research and development in process for the quarter ending 2019-09-30 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. research and development in process for fiscal 2019 was $78.90M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $0.00 derived: sum of 2 quarters · filed 2021-03-30 | $78.90M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $78.90M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $78.90M 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |